natgillin/translations-raw huggingface dataset:
After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues outstanding.
Potem ko je CHMP ocenil odgovore podjetja na seznam vprašanj, so nekatera tehtna vprašanja še vedno ostala nerešena.
It works by blocking the action of enzymes that are necessary for the bacteria to make DNA.
Deluje tako, da blokira delovanje encimov, ki je potrebno, da bi bakterije lahko tvorile DNK.
On 25 July 2007, Schering-Plough Europe officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Garenoxacin mesylate 400 mg and 600 mg film-coated tablets and 2 mg/ml solution for infusion, for the treatment of bacterial infections.
Podjetje Schering-Plough Europe je dne 25. julija 2007 obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da se je odločilo umakniti vlogo za izdajo dovoljenja za promet z zdravilom Garenoksacin mesilat, v obliki 400 in 600 mg filmsko obloženih tablet in 2 mg/ml raztopine za infundiranje, namenjenim za zdravljenje bakterijskih okužb.
By blocking these enzymes, garenoxacin mesylate prevents certain types of bacteria from growing and multiplying.
Z blokiranjem teh encimov garenoksacin mesilat prepreči rast in razmnoževanje določenih vrst bakterij.
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Garenoxacin mesylate could not have been approved for the treatment of bacterial infections.
Na podlagi pregleda podatkov in odgovorov podjetja na seznam vprašanj, ki jih je zastavil CHMP, je imel Odbor v času umika vloge določene zadržke in bil začasnega mnenja, da zdravila Garenoksacin mesilat ni mogoče odobriti za zdravljenje bakterijskih okužb.
What are the consequences of the withdrawal for patients undergoing clinical trials with Garenoxacin mesylate?
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih zdravila Garenoksacin mesilat?
Garenoxacin mesylate was examined in 19 studies involving a total of over 7,000 patients with the types of bacterial infection that the medicine was expected to be used to treat.
Zdravilo Garenoksacin mesilat so preučevali v 19 študijah, v katerih je sodelovalo skupaj več kot 7000 bolnikov z vrstami bakterijskih okužb, za zdravljenje katerih bi se naj zdravilo uporabljalo.
The effects of Garenoxacin mesylate were first tested in experimental models before being studied in humans.
Učinki zdravila Garenoksacin mesilat so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Garenoxacin mesylate is a medicine that was to be available as tablets (400 mg and 600 mg) and as a solution for infusion (drip into a vein).
Garenoksacin mesilat je zdravilo, ki bi naj bilo na voljo v obliki tablet (400 mg in 600 mg) in raztopine za infundiranje (dajanje v veno).
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for GARENOXACIN MESYLATE
VPRAŠANJA IN ODGOVORI GLEDE UMIKA VLOGE ZA IZDAJO DOVOLJENJA ZA PROMET za zdravilo GARENOKSACIN MESILAT
• complicated intra-abdominal infections, including infections after surgery and acute infections of the pelvis.
• zapletenimi intraabdominalnimi okužbami, vključno z okužbami po kirurških posegih in akutnimi okužbami v medenici.
Garenoxacin mesylate was expected to be used to treat adults with the following infections:
Zdravilo Garenoksacin mesilat bi se naj uporabljalo za zdravljenje odraslih z naslednjimi okužbami:
Garenoxacin mesylate is an antibiotic that belongs to the ‘quinolone' class.
Zdravilo Garenoksacin mesilat je antibiotik, ki sodi v razred kinolonov.
The company informed the CHMP that no further patients are being enrolled into clinical trials with Garenoxacin mesylate, and that there are no consequences for patients already included in these trials.
Podjetje je CHMP obvestilo, da v klinična preizkušanja zdravila Garenoksacin mesilat ne vključujejo več novih bolnikov, ter da za bolnike, ki že sodelujejo v kliničnih preizkušanjih, ni nikakršnih posledic.
• acute bacterial sinusitis (short-lived infection of the sinuses, air-filled passageways in the bones around the nose and eyes),
• akutnim bakterijskim sinusitisom (kratkotrajno okužbo sinusov, z zrakom napolnjenih votlin v kosteh okrog nosu in oči)
• acute bacterial exacerbation (flare-up) of chronic bronchitis (long-lasting inflammation of the airways in the lungs),
• akutnim bakterijskim poslabšanjem kroničnega bronhitisa (dolgotrajnega vnetja dihalnih poti v pljučih),
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Garenoxacin mesylate had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Zato je bil v času umika CHMP mnenja, da koristi zdravila Garenoksacin mesilat niso zadostno dokazane in da niso večje od znanih tveganj.
Garenoxacin mesylate was only to be used when these infections were known to be caused by bacteria that are susceptible to the medicine.
Zdravilo Garenoksacin mesilat bi se naj uporabljalo samo v primerih, ko bi bilo znano, da so vzrok teh okužb bakterije, občutljive na to zdravilo.
• community-acquired pneumonia (an infection of the lungs that is caught outside of hospital),
• zunajbolnišnično pljučnico (okužbo pljuč, nastalo izven bolnišnice),
• infections of the skin and the tissue just below the skin, including foot infections in patients with diabetes,
• okužbami kože in podkožnega tkiva, vključno z okužbo stopal pri sladkornih bolnikih,
What is Garenoxacin mesylate?
Kaj je zdravilo Garenoksacin mesilat?
How is Garenoxacin mesylate expected to work?
Kako naj bi zdravilo Garenoksacin mesilat delovalo?
What was Garenoxacin mesylate expected to be used for?
Za kaj naj bi se zdravilo Garenoksacin mesilat uporabljalo?
The potential risk for humans is unknown.
Potencialno tveganje za človeka ni znano.
After that carry on as normal.
Po tem nadaljujte jemanje kot običajno.
In individual cases, only some of these symptoms and/or findings may be evident.
V posameznih primerih so lahko prisotni le nekateri od teh simptomov in/ali izsledkov preiskav.
- You should take only one tablet each time.
- Vsakič vzemite samo eno tableto.
Date of first authorisation: 24 August 2011 Date of latest renewal: 26 May 2016
Datum prve odobritve: 24. avgust 2011 Datum zadnjega podaljšanja: 26. maj 2016
Consult your doctor if you think this applies to you.
Posvetujte se z vašim zdravnikom, če menite, da velja to tudi za vas.
This may cause difficulties in breathing or swallowing.
To lahko povzroči težave z dihanjem ali požiranjem.
To open the bottle for the first time: open the closure, and then press with your thumb on the seal until it breaks.
Da prvič odprete steklenico: odprite zamašek in nato pritisnite s palcem navzdol na pregrado dokler se ne zlomi.
Otherwise, you may put yourself and others at risk of serious injury or death.
Če tega ne upoštevate, lahko izpostavite sebe in druge tveganju resne poškodbe ali smrti.
Accordingly, to date there has been no indication of such interactions.
Glede na to do sedaj niso bile ugotovljene tovrstne interakcije.
Therefore, be particularly careful when you drive or when you use any tools or machines.
Zato bodite še posebej pazljivi, če vozite ali uporabljate kakršna koli orodja ali stroje.
Dose reduction may be needed (see section 5.2).
Lahko da bo potrebno zmanjšati odmerek (glejte poglavje 5.2).
After taking one of them, wait at least 2 to 3 hours before taking the other.
Ko vzamete eno od obojega, počakajte najmanj 2 do 3 ure preden vzamete drugo zdravilo.
The INR values increased on average by 13% [CI90 6-19%].
Vrednosti INR so se povečale v povprečju za 13 % [CI90 6-19 %].
- Depending on how you respond to treatment, your doctor may suggest a higher or lower dose.
- Glede na to, kako se odzivate na zdravljenje, bo vaš zdravnik lahko predlagal večji ali manjši odmerek.
This corresponded to an 8.3% increase in the proportion of daily ON time.
To je odgovarjalo povečanju razmerja dnevnega trajanja tega intervala za 8,3 %.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
Your doctor may need to review your treatments.
Vaš zdravnik bo moral morda preveriti ustreznost vašega zdravljenja.
[carton only]:
[samo škatla]:
Psychosis, agitation*
psihoza, vznemirjenost*
Hepatitis with mainly cholestatic features (see section 4.4)*
hepatitis s pretežno holestatskimi značilnostmi (glejte poglavje 4.4)*
Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see also section 4.8).
Pred uvedbo zdravljenja je treba bolnike in negovalce opozoriti o možnem tveganju za razvoj DDS (glejte tudi poglavje 4.8).
Many of the side effects can be relieved by adjusting the dose.
Mnoge od teh učinkov se da odpraviti s prilagajanjem odmerka.
The early diagnosis is important for the appropriate management of NMS.
Za ustrezno obravnavo NMS je pomembna zgodnja diagnoza.
Neuroleptic malignant syndrome*
nevroleptični maligni sindrom*
Patients with past or current psychosis should be treated with caution.
Pri zdravljenju bolnikov s preteklo ali obstoječo psihozo je potrebna previdnost.
In the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.
V primeru dolgotrajne ali trdovratne diareje je treba zdravljenje prekiniti in razmisliti o ustreznem zdravljenju in preiskavah.
Dose adjustment during the course of the treatment
Prilagajanje odmerka med zdravljenjem
Reduction of levodopa dose decreases the severity and frequency of these dopaminergic reactions.
Zmanjšanje odmerka levodope zmanjša resnost in pogostnost teh dopaminergičnih reakcij.
Therefore, any abrupt dose reduction or withdrawal of levodopa should be carefully observed, particularly in patients who are also receiving neuroleptics.
Zato je treba vsako nenadno zmanjšanje odmerka ali ukinitev levodope skrbno spremljati, zlasti pri bolnikih, ki prejemajo tudi nevroleptike.
If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert.
Če postanete nenadoma zelo zaspani ali se vam zgodi, da v trenutku zaspite, počakajte, dokler ne boste zopet popolnoma budni, preden vozite ali počnete karkoli, kar zahteva, da ste pozorni.
See picture 1.
Glejte sliko 1.
In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change.
V primeru prevelikega odmerka se lahko počutite zmedene ali vznemirjene, srčni utrip je lahko počasnejši ali hitrejši od običajnega in barva kože, jezika, oči ali urina se lahko spremeni.
However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for Rwarfarin increased on average by 18% [CI90 11-26%].
Vendar pa v raziskavi interakcij pri zdravih prostovoljcih entakapon ni povzročil spremembe plazemskih koncentracij S-varfarina, med tem, ko so se vrednosti AUC R-varfarina povečale v povprečju za 18 % [CI90 11-26 %].
This may hasten the elimination of entacapone in particular by decreasing its absorption/reabsorption from the GI tract.
To lahko pospeši odstranjevanje entakapona s tem, da zmanjšuje njegovo absorpcijo/resorpcijo iz prebavnega trakta.
- Patients should be regularly monitored for the development of impulse control disorders.
- Bolnike je treba redno spremljati zaradi možnosti razvoja motenj pri obvladovanju impulzov.
Pharmacotherapeutic group: anti-parkinson drugs, dopa and dopa derivatives, ATC code: N04BA03
Farmakoterapevtska skupina: antiparkinsonik, dopa in derivati dope, oznaka ATC: N04BA03
No pharmacodynamic interactions were observed.
Farmakodinamičnih interakcij niso opazili.
Food does not significantly affect the absorption of entacapone.
Hrana bistveno ne vpliva na absorpcijo entakapona.
The value of dialysis in the treatment of overdose is not known.
Koristnost dialize pri zdravljenju prevelikega odmerjanja ni znana.
If it is more than 1 hour until your next dose: Take one tablet as soon as you remember, and the next tablet at the normal time.
Če je do naslednjega odmerka več kot 1 uro časa: vzemite eno tableto takoj, ko se spomnite, drugo pa ob normalnem času za odmerek.
even if their symptoms signs of illness are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
Both levodopa and entacapone are rapidly absorbed and eliminated.
Tako levodopa kot entakapon se hitro absorbirata in izločata.
PC: {number} SN: {number} < NN: {number} >
PC: {številka} SN: {številka} < NN: {številka}>
For severe hepatic impairment see section 4.3.
Za hudo okvaro jeter glejte poglavje 4.3.
See section c.
Glejte poglavje c.
The optimum daily dose must be determined by careful titration of levodopa in each patient.
Optimalni dnevni odmerek je treba določiti s pomočjo skrbne titracije levodope pri vsakem posameznem bolniku.
The use of glucose oxidase methods may give false negative results for glycosuria.
Uporaba metod z glukoza-oksidazo lahko povzroči lažno negativne rezultate za glikozurijo.
Consequently the clinical response to each dose of levodopa is enhanced and prolonged.
Skladno s tem je klinični odgovor na vsak posamezni odmerek levodope močnejši in dolgotrajnejši.
Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting.
Pri bolnikih, ki dobivajo manj kot 70-100 mg karbidope dnevno, obstaja večja verjetnost pojava slabosti in bruhanja.
Levodopa is bound to plasma protein only to a minor extent of about 10-30% and carbidopa is bound approximately 36%, while entacapone is extensively bound to plasma proteins (about 98%) -mainly to serum albumin.
Levodopa se le v manjši meri veže na proteine v plazmi (približno 10-30 %), karbidopa pa v približno 36 %, med tem ko se entakapon veže na proteine v plazmi v veliki meri (približno 98 %) - pretežno na serumski albumin.
The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed.
Ustreznost delovanja dihal, krvnega obtoka in ledvic je treba skrbno nadzorovati in po potrebi uvesti odgovarjajoče podporne ukrepe.
Orthostatic hypotension, hypertension
ortostatska hipotenzija, hipertenzija
The SmPC section 4.4 and 4.8 are being updated to add Dopamine Dysregulation Syndrome (DDS) with a frequency “not known” and to add further explanation with regards to DDS to section 4.8 to increase awareness and understanding on the pathology and add a warning to section 4.4 to recommend relevant precautions.
Poglavji 4.4 in 4.8 SmPC-ja sta bili posodobljeni, dodan je bil sindrom motene regulacije dopamina (DDS) s pogostnostjo »ni znano«; v poglavje 4.8 je bila dodana dodatna obrazložitev glede sindroma motene regulacije dopamina z namenom povečanja ozaveščenosti in razumevanja patologije ter dodano opozorilo v poglavje 4.4 s priporočilom posebnih previdnostnih ukrepov.
Suicidal behaviour, Dopamine dysregulation syndrome
samomorilno vedenje, sindrom motene regulacije dopamina
- For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.
- Za bolnike, ki izkusijo progresivno anoreksijo, astenijo ali zmanjšanje telesne mase v relativno kratkem obdobju je treba razmisliti o splošnem zdravniškem pregledu, vključno z delovanjem jeter.
In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms.
V takem primeru bo morda vaš zdravnik moral prilagoditi odmerjanje drugih antiparkinsonskih zdravil, ki jih jemljete, zlasti levodope, za zadovoljivo obvladovanje vaših simptomov.
Consult your doctor if you are currently taking: - antipsychotics (medicines used to treat psychosis) - a medicine which may cause low blood pressure when rising from a chair or bed.
Posvetujte se z zdravnikom, če trenutno jemljete: - antipsihotike (zdravila, ki se uporabljajo za zdravljenje psihoze); - zdravila, zaradi katerih se vam lahko pri vstajanju s stola ali postelje zniža krvni tlak.
If required, appropriate anti-arrhythmic therapy should be given.
Po potrebi je treba uvesti zdravljenje z ustreznimi antiaritmiki.
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti po naslednjem dogovoru: Zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), neznani (ni jih možno oceniti z razpoložljivimi podatki, saj ustrezna ocena iz kliničnih preskušanj ali epidemioloških študij ni mogoča).
One tablet contains one treatment dose and the tablet may only be administered as whole tablets.
Ena tableta vsebuje enkratni terapevtski odmerek, tablete pa se smejo jemati le cele.
Unchanged carbidopa accounts for 30% of the total urinary excretion.
Karbidopa v nespremenjeni obliki predstavlja 30 % vseh oblik, ki se izločajo v urinu.
Carbidopa and entacapone were excreted in milk in animals but is not known whether they are excreted in human breast milk.
Karbidopa in entakapon sta se izločala v mleku živali, ni pa znano, ali se izločata tudi v materino mleko.
**The incidence rates of myocardial infarction and other ischemic heart disease events (0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone.
**Stopnja incidence miokardnega infarkta in drugih dogodkov ishemičnih srčnih bolezni (0,43 % in 1,54 %) so izpeljani iz analize 13 dvojno slepih študij, ki so zajemale 2.082 bolnikov z motorno fluktuacijo ob koncu odmerjanja ob prejemanju entakapona.
Entacapone is almost completely metabolized prior to excretion via urine (10 to 20%) and bile/faeces (80 to 90%).
Entakapon se skoraj v celoti presnovi, preden se izloči z urinom (10-20 %) in preko žolča/blata (8090 %).
Since the introduction of entacapone into the market, isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone and other concomitant dopaminergic medicinal products.
Od uvedbe entakapona na tržišče poročajo o posameznih primerih NMS, zlasti po nenadnem zmanjšanju ali ukinitvi entakapona in drugih sočasnih dopaminergičnih zdravil.
The main metabolic pathway is glucuronidation of entacapone and its active metabolite, the cis-isomer, which accounts for about 5% of plasma total amount.
Glavna presnovna pot je glukuronizacija entakapona in njegovega aktivnega presnovka cisizomera, ki predstavlja približno 5 % celotne količine v plazmi.
Parkinson's disease is caused by low levels of a substance called dopamine in the brain.
Parkinsonovo bolezen povzročajo nizke ravni snovi, ki se imenuje dopamin, v možganih.
The Package leaflet is updated accordingly.
Navodilo za uporabo je bilo ustrezno posodobljeno.
ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias.
Uvesti je treba tudi nadzor z EKG in bolnika skrbno spremljati zaradi morebitnega pojava aritmij.
If any of this happens, contact your doctor immediately - feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour - find yourself suddenly falling asleep, or if you feel very drowsy.
Če opazite karkoli od zgoraj navedenega, se takoj posvetujte s svojim zdravnikom; - počutite depresivne, imate samomorilne misli ali opazite nenavadne spremembe v svojem vedenju; - nenadoma zaspite ali se počutite zelo zaspani.
In the second study, the mean proportion of daily ON time increased by 4.5% (CI95% 0.93%, 7.97%) from baseline.
V drugi raziskavi se je srednje razmerje dnevnega trajanja intervala »ON« povečalo za 4,5 % (CI95% 0,93 %, 7,97 %) glede na izhodiščne vrednosti.
Contains sucrose.
Vsebuje saharozo.
Elderly: When given without carbidopa and entacapone, the absorption of levodopa is greater and elimination is slower in elderly than in young people.
Starejši: Kadar se levodopa daje brez karbidope in entakapona, je pri starejših njena absorpcija večja, izločanje pa počasnejše kot pri mlajših osebah.
Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson's disease.
Levodopa povečuje količino dopamina in tako zmanjša simptome Parkinsonove bolezni.
Therefore, caution should be exercised when driving or using machines.
Zato je pri vožnji in upravljanju strojev potrebna previdnost.
Weight decreased*, decreased appetite*
zmanjšanje telesne mase*, zmanjšanje apetita*
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je vaš zdravnik povedal, da ne prenašate nekaterih vrst sladkorja, se posvetujte z njim, preden začnete jemati to zdravilo.
In vitro data: Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen.
Podatki in vitro: Entakapon se veže na vezavno mesto II v humanem albuminu, kamor se vežejo še mnoga druga zdravila, vključno z diazepamom in ibuprofenom.
Prolonged or persistent diarrhoea appearing during use of entacapone may be a sign of colitis.
Dolgotrajna ali trdovratna diareja, do katere pride med uporabo entakapona, je lahko znak kolitisa.
Gender: Bioavailability of levodopa is significantly higher in women than in men.
Spol: Biološka uporabnost levodope je pri ženskah značilno višja kot pri moških.
The daily dose of levodopa can be reduced by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient.
Dnevni odmerek levodope se lahko zmanjša s podaljšanjem odmernega obdobja in/ali z zmanjšanjem količine levodope na odmerek, glede na klinično stanje bolnika.
Entacapone in high doses may affect the absorption of carbidopa.
Visoki odmerki entakapona lahko vplivajo na absorpcijo karbidope.
Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers.
Interakcije med entakaponom in imipraminom ter med entakaponom in moklobemidom so proučevali v raziskavah z enkratnimi odmerki pri zdravih prostovoljcih.
For some patients, Levodopa/Carbidopa/Entacapone Orion may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts).
Pri nekaterih bolnikih se zdravilo Levodopa/Carbidopa/Entacapone Orion ne absorbira tako dobro, če ga jemljejo med obrokom ali kmalu po obroku proteinsko bogate hrane (npr. meso, ribe, mlečni izdelki, semena in oreški).
- Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat.
- Alergijske reakcije, znaki so lahko osip (koprivnica), srbenje, izpuščaj, oteklost obraza, ustnic, jezika ali grla.
Meals rich in large neutral amino acids may delay and reduce the absorption of levodopa.
Obroki, ki vsebujejo veliko nevtralnih aminokislin, lahko upočasnijo ali zmanjšajo absorpcijo levodope.